Daclizumab Completed Phase 2 Trials for Uveitis / Retinal Diseases / Behcet's Syndrome Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00070759Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00043667Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
NCT00001865HAT in Eye Complications of Behcet's Disease